2019 CSCO China, with highlights on proteomics-driven precision medicine, oncology treatment and quality control, and breakthroughs in drug developments
The 22nd annual installment of the Chinese Society of Clinical Oncology (CSCO) meeting, took place at the Xiamen International Conference Center on September 19, for 4 days. The theme of the 22nd conference was “Precision & Intelligence: Hope to conquer cancer”. The conference had four aims: (1) Encourage the exchange of new knowledge and technology in clinical oncology; (2) Promote scientific exchange between China and other countries; (3) Support academic research; (4) Support innovation in the industry. The conference attracted approximately 30,000 participants, more than 600 speakers and paper presenters from China and abroad, and 275 manufacturers from China. Geneonline attended the CSCO meeting, and reported the highlights of this conference.
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence